This on-demand panel discussion provides a review of the current policies and regulations that drive costs related to biomarker testing.

• Gabriel Bien-Willner, MD, PhD, Medical Director, MolDX; Chief Medical Officer, Palmetto GBA
• Hossein Borghaei, DO, MS, Professor and Chief, Thoracic Oncology, The Gloria and Edmund M. Dunn Chair in Thoracic Oncology, Department of Hematology and Oncology, Fox Chase Cancer Center

Speakers review current policies and regulations that drive costs related to biomarker testing.
Register